Document is current
Any future updates will be listed below
-
Authors
Good, Misty
Chu, Tianjiao
Shaw, Patricia
Nolan, Lila S.
Wrobleski, Joseph
Castro, Carlos
Gong, Qingqing
DeWitt, Olivia
Finegold, David N.
Peters, David https://orcid.org/0000-0003-4354-1125
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01DK118568, R01DK124614, R01HD105301, F32DK130248)
Necrotizing Enterocolitis Society
St. Louis Children's Hospital Foundation
Children's Discovery Institute
Department of Pediatrics, Washington University School of Medicine
American Academy of Pediatrics
Pittsburgh Health Data Alliance
Magee-Womens Research Institute
- License Information
-
More Information
Article History
Received: 27 November 2021
Accepted: 21 March 2022
First Online: 11 April 2022
Declarations
:
: The intestinal samples in this study were collected in accordance with the University of Pittsburgh anatomical tissue procurement guidelines. Collection was approved by the Institutional Review Board (IRB) of the University of Pittsburgh (Protocols PRO09110437 or PRO14070508). Preterm infants were recruited under Protocol PRO09110437 at either Children’s Hospital of Pittsburgh (CHP) of University of Pittsburgh Medical Center (UPMC) or Magee-Womens Hospital Neonatal Intensive Care Units (NICUs), and consent was obtained from their parent or legal guardian.
: Not applicable.
: DP is a founder and Chief Science Officer of Signature Diagnostics. TJ is a founder and Chief Technology Officer of Signature Diagnostics. DF is a consultant for Signature Diagnostics. Signature Diagnostics had no role in this study. MG has received sponsored research agreement funding from Takeda Pharmaceuticals and Evive Biotech in the past year, neither of which had any role in this study.
